Conmed Corp Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $1.4B+4.9% YoYTTM through 30 Jun 2026
Net Income $56.5M-57.3% YoYTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 57.9% |
| EBITDA Margin | 11.8% |
| Operating Margin | 8.0% |
| Net Margin | 4.1% |
Returns
5.4%ROE
2.4%ROA
3.4%ROIC
Balance Sheet Health
Debt / Equity0.85x
Current Ratio2.29x
Net Debt$825.8M
Cash & Equivalents$37.3M
Quality Metrics
Altman Z-Score1.91
Earnings-Beat Rate100.0%
Multi-Year Trend
RevenueFY2025: $1.4B
Diluted EPS$1.85TTMFY2025: $1.51
Dividend
$0.60Per share, FY20251.30%Yield-5.6%5-yr growth
Capital Allocation
R&D Spend$60.6M
Capex Intensity0.9%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Orthopedics | +4.5% | View detailsFocus remains on resolving supply chain challenges and driving growth in soft tissue repair and foot and ankle offerings. | |
| General Surgery | -8.5% | View detailsGrowth is driven by minimally invasive surgery and smoke evacuation platforms, specifically AirSeal and Buffalo Filter. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.